Patient-driven discovery and post-clinical validation of NTRK3 fusion as an acquired resistance mechanism to selpercatinib in RET fusion-positive lung cancer
Titel:
Patient-driven discovery and post-clinical validation of NTRK3 fusion as an acquired resistance mechanism to selpercatinib in RET fusion-positive lung cancer
Auteur:
Subbiah, V. Shen, T. Tetzlaff, M. Weissferdt, A. Byers, L.A. Cascone, T. Behrang, A. Meric-Bernstam, F. Mooers, B.H.M. Rothenberg, S.M. Ebata, K. Wu, J.